Cancer Immunology, Immunotherapy

, Volume 57, Issue 7, pp 1017–1027

A33 antigen displays persistent surface expression

  • Margaret E. Ackerman
  • Cecile Chalouni
  • Michael M. Schmidt
  • Vivek V. Raman
  • Gerd Ritter
  • Lloyd J. Old
  • Ira Mellman
  • K. Dane Wittrup
Original Article

Abstract

The A33 antigen is a cell surface glycoprotein of the small intestine and colonic epithelium with homology to tight junction-associated proteins of the immunoglobulin superfamily, including CAR and JAM. Its restricted tissue localization and high level of expression have led to its use as a target in colon cancer immunotherapy. Although the antigen is also present in normal intestine, radiolabeled antibodies against A33 are selectively retained by tumors in the gut as well as in metastatic lesions for as long as 6 weeks. Accordingly, we have studied the trafficking and kinetic properties of the antigen to determine its promise in two-step, pretargeted therapies. The localization, mobility, and persistence of the antigen were investigated, and this work has demonstrated that the antigen is both highly immobile and extremely persistent—retaining its surface localization for a turnover halflife of greater than 2 days. In order to explain these unusual properties, we explored the possibility that A33 is a component of the tight junction. The simple property of surface persistence, described here, may contribute to the prolonged retention of the clinically administered antibodies, and their uncommon ability to penetrate solid tumors.

Keywords

A33 antigen Radioimmunotherapy Colon cancer Tight junction Immunoglobulin superfamily 

References

  1. 1.
    DeNardo GL (2005) Treatment of non-Hodgkin’s lymphoma (NHL) with radiolabeled antibodies (mAbs). Semin Nucl Med 35(3):202–211PubMedCrossRefGoogle Scholar
  2. 2.
    Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, Theodore LJ, Wilbur DS, Matthews DC, Press OW (2003) Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 101(6):2340–2348PubMedCrossRefGoogle Scholar
  3. 3.
    Gruaz-Guyon A, Raguin O, Barbet J (2005) Recent advances in pretargeted radioimmunotherapy. Curr Med Chem 12(3):319–338PubMedGoogle Scholar
  4. 4.
    Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH (2003) Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 44(3):400–411PubMedGoogle Scholar
  5. 5.
    Johnstone CN, Tebbutt NC, Abud HE, White SJ, Stenvers KL, Hall NE, Cody SH, Whitehead RH, Catimel B, Nice EC, Burgess AW, Heath JK (2000) Characterization of mouse A33 antigen, a definitive marker for basolateral surfaces of intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 279(3):G500–G510PubMedGoogle Scholar
  6. 6.
    Heath JK, White SJ, Johnstone CN, Catimel B, Simpson RJ, Moritz RL, Tu GF, Ji H, Whitehead RH, Groenen LC, Scott AM, Ritter G, Cohen L, Welt S, Old LJ, Nice EC, Burgess AW (1997) The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci USA 94(2):469–474PubMedCrossRefGoogle Scholar
  7. 7.
    Garin-Chesa P, Sakamoto J, Welt S, Real FX, Rettig WJ, Old LJ (1996) Organ-specific expression of the colon cancer antigen A33, a cell suface target for antibody-based therapy. Int J Oncol 9:465–471Google Scholar
  8. 8.
    Welt S, Divgi CR, Real FX, Yeh SD, Garin-Chesa P, Finstad CL, Sakamoto J, Cohen A, Sigurdson ER, Kemeny N et al (1990) Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. J Clin Oncol 8(11):1894–1906PubMedGoogle Scholar
  9. 9.
    Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, Germain JS, Richards EC, Larson SM, Oettgen HF et al (1994) Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 12(8):1561–1571PubMedGoogle Scholar
  10. 10.
    Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, Germain JS, Richards EC, Larson SM, Old LJ (1996) Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 14(6):1787–1797PubMedGoogle Scholar
  11. 11.
    Welt S, Ritter G, Williams C Jr, Cohen LS, John M, Jungbluth A, Richards EA, Old LJ, Kemeny NE (2003) Phase I study of anticolon cancer humanized antibody A33. Clin Cancer Res 9(4):1338–1346PubMedGoogle Scholar
  12. 12.
    Scott AM, Lee FT, Jones R, Hopkins W, MacGregor D, Cebon JS, Hannah A, Chong G, Paul U, Papenfuss A, Rigopoulos A, Sturrock S, Murphy R, Wirth V, Murone C, Smyth FE, Knight S, Welt S, Ritter G, Richards E, Nice EC, Burgess AW, Old LJ (2005) A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res 11(13):4810–4817PubMedCrossRefGoogle Scholar
  13. 13.
    Chong G, Lee FT, Hopkins W, Tebbutt N, Cebon JS, Mountain AJ, Chappell B, Papenfuss A, Schleyer P, Paul U, Murphy R, Wirth V, Smyth FE, Potasz N, Poon A, Davis ID, Saunder TJ, O’Keefe G, Burgess AW, Hoffman EW, Old LJ, Scott AM (2005) Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res 11(13):4818–4826PubMedCrossRefGoogle Scholar
  14. 14.
    Ritter G, Cohen LS, Williams C Jr, Richards EC, Old LJ, Welt S (2001) Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 61(18):6851–6859PubMedGoogle Scholar
  15. 15.
    Johnstone CN, White SJ, Tebbutt NC, Clay FJ, Ernst M, Biggs WH, Viars CS, Czekay S, Arden KC, Heath JK (2002) Analysis of the regulation of the A33 antigen gene reveals intestine-specific mechanisms of gene expression. J Biol Chem 277(37):34531–34539PubMedCrossRefGoogle Scholar
  16. 16.
    Chen CJ, Shively JE (2004) The cell–cell adhesion molecule carcinoembryonic antigen-related cellular adhesion molecule 1 inhibits IL-2 production and proliferation in human T cells by association with Src homology protein-1 and down-regulates IL-2 receptor. J Immunol 172(6):3544–3552PubMedGoogle Scholar
  17. 17.
    Ellenberg J, Siggia ED, Moreira JE, Smith CL, Presley JF, Worman HJ, Lippincott-Schwartz J (1997) Nuclear membrane dynamics and reassembly in living cells: targeting of an inner nuclear membrane protein in interphase and mitosis. J Cell Biol 138(6):1193–1206PubMedCrossRefGoogle Scholar
  18. 18.
    Umenishi F, Verbavatz JM, Verkman AS (2000) cAMP regulated membrane diffusion of a green fluorescent protein-aquaporin 2 chimera. Biophys J 78(2):1024–1035PubMedGoogle Scholar
  19. 19.
    Partikian A, Olveczky B, Swaminathan R, Li Y, Verkman AS (1998) Rapid diffusion of green fluorescent protein in the mitochondrial matrix. J Cell Biol 140(4):821–829PubMedCrossRefGoogle Scholar
  20. 20.
    Le TL, Yap AS, Stow JL (1999) Recycling of E-cadherin: a potential mechanism for regulating cadherin dynamics. J Cell Biol 146(1):219–232PubMedCrossRefGoogle Scholar
  21. 21.
    Ji H, Moritz RL, Reid GE, Ritter G, Catimel B, Nice E, Heath JK, White SJ, Welt S, Old LJ, Burgess AW, Simpson RJ (1997) Electrophoretic analysis of the novel antigen for the gastrointestinal-specific monoclonal antibody, A33. Electrophoresis 18(3–4):614–621PubMedCrossRefGoogle Scholar
  22. 22.
    Daghighian F, Barendswaard E, Welt S, Humm J, Scott A, Willingham MC, McGuffie E, Old LJ, Larson SM (1996) Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody. J Nucl Med 37(6):1052–1057PubMedGoogle Scholar
  23. 23.
    Bruewer M, Utech M, Ivanov AI, Hopkins AM, Parkos CA, Nusrat A (2005) Interferon-gamma induces internalization of epithelial tight junction proteins via a macropinocytosis-like process. Faseb J 19(8):923–933PubMedCrossRefGoogle Scholar
  24. 24.
    Kevil CG, Oshima T, Alexander B, Coe LL, Alexander JS (2000) H(2)O(2)-mediated permeability: role of MAPK and occludin. Am J Physiol Cell Physiol 279(1):C21–C30PubMedGoogle Scholar
  25. 25.
    Harhaj NS, Antonetti DA (2004) Regulation of tight junctions and loss of barrier function in pathophysiology. Int J Biochem Cell Biol 36(7):1206–1237PubMedCrossRefGoogle Scholar
  26. 26.
    Musch MW, Walsh-Reitz MM, Chang EB (2006) Roles of ZO-1, occludin, and actin in oxidant-induced barrier disruption. Am J Physiol Gastrointest Liver Physiol 290(2):G222–G231PubMedCrossRefGoogle Scholar
  27. 27.
    Ivanov AI, Nusrat A, Parkos CA (2004) Endocytosis of epithelial apical junctional proteins by a clathrin-mediated pathway into a unique storage compartment. Mol Biol Cell 15:176–188PubMedCrossRefGoogle Scholar
  28. 28.
    Mandell KJ, Parkos CA (2005) The JAM family of proteins. Adv Drug Deliv Rev 57(6):857–867PubMedCrossRefGoogle Scholar
  29. 29.
    Gray-Owen SD, Blumberg RS (2006) CEACAM1: contact-dependent control of immunity. Nat Rev Immunol 6(6):433–446PubMedCrossRefGoogle Scholar
  30. 30.
    Kostrewa D, Brockhaus M, D’Arcy A, Dale GE, Nelboeck P, Schmid G, Mueller F, Bazzoni G, Dejana E, Bartfai T, Winkler FK, Hennig M (2001) X-ray structure of junctional adhesion molecule: structural basis for homophilic adhesion via a novel dimerization motif. Embo J 20(16):4391–4398PubMedCrossRefGoogle Scholar
  31. 31.
    Brummendorf T, Lemmon V (2001) Immunoglobulin superfamily receptors: cis-interactions, intracellular adapters and alternative splicing regulate adhesion. Curr Opin Cell Biol 13(5):611–618PubMedCrossRefGoogle Scholar
  32. 32.
    Walters RW, Freimuth P, Moninger TO, Ganske I, Zabner J, Welsh MJ (2002) Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape. Cell 110(6):789–799PubMedCrossRefGoogle Scholar
  33. 33.
    Mullin JM, Agostino N, Rendon-Huerta E, Thornton JJ (2005) Keynote review: epithelial and endothelial barriers in human disease. Drug Discov Today 10(6):395–408PubMedCrossRefGoogle Scholar
  34. 34.
    Sawada N, Murata M, Kikuchi K, Osanai M, Tobioka H, Kojima T, Chiba H (2003) Tight junctions and human diseases. Med Electron Microsc 36(3):147–156PubMedCrossRefGoogle Scholar
  35. 35.
    Mullin JM (2004) Epithelial barriers, compartmentation, and cancer. Sci STKE 2004(216):pe2PubMedGoogle Scholar
  36. 36.
    Soler AP, Miller RD, Laughlin KV, Carp NZ, Klurfeld DM, Mullin JM (1999) Increased tight junctional permeability is associated with the development of colon cancer. Carcinogenesis 20(8):1425–1431PubMedCrossRefGoogle Scholar
  37. 37.
    Ivanov AI, McCall IC, Babbin B, Samarin SN, Nusrat A, Parkos CA (2006) Microtubules regulate disassembly of epithelial apical junctions. BMC Cell Biol 7:12PubMedCrossRefGoogle Scholar
  38. 38.
    Furuse M, Itoh M, Hirase T, Nagafuchi A, Yonemura S, Tsukita S, Tsukita S (1994) Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions. J Cell Biol 127(6):1617–1626PubMedCrossRefGoogle Scholar
  39. 39.
    Li Y, Fanning AS, Anderson JM, Lavie A (2005) Structure of the conserved cytoplasmic C-terminal domain of occludin: identification of the ZO-1 binding surface. J Mol Biol 352:151–164PubMedCrossRefGoogle Scholar
  40. 40.
    Cliffe A, Mieszczanek J, Bienz M (2004) Intracellular shuttling of a Drosophila APC tumour suppressor homolog. BMC Cell Biology 5:37PubMedCrossRefGoogle Scholar
  41. 41.
    Thomas T, Jordan K, Simek J, Shao Q, Jedeszko C, Walton P, Laird DW (2005) Mechanisms of Cx43 and Cx26 transport to the plasma membrane and gap junction regeneration. J Cell Sci 119:4451–4462CrossRefGoogle Scholar
  42. 42.
    Kirshner J, Schumann D, Shively JE (2003) CEACAM1, a cell–cell adhesion molecule, directly associates with annexin II in a three-dimensional model of mammary morphogenesis. J Biol Chem 278(50):50338–50435PubMedCrossRefGoogle Scholar
  43. 43.
    Schumann D, Chen CJ, Kaplan B, Shively JE (2001) Carcinoembryonic antigen cell adhesion molecule 1 directly associates with cytoskeleton proteins actin and tropomyosin. J Biol Chem 276(50):47421–47433PubMedCrossRefGoogle Scholar
  44. 44.
    Hammarstrom S (1999) The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9(2):67–81PubMedCrossRefGoogle Scholar
  45. 45.
    Chretien I, Marcuz A, Courtet M, Katevuo K, Vainio O, Heath JK, White SJ, Du Pasquier L (1998) CTX, a Xenopus thymocyte receptor, defines a molecular family conserved throughout vertebrates. Eur J Immunol 28(12):4094–4104PubMedCrossRefGoogle Scholar
  46. 46.
    Bazzoni G (2003) The JAM family of junctional adhesion molecules. Curr Opin Cell Biol 15(5):525–530PubMedCrossRefGoogle Scholar
  47. 47.
    Kuespert K, Pils S, Hauck CR (2006) CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol 18:565–571PubMedCrossRefGoogle Scholar
  48. 48.
    van Osdol W, Fujimori K, Weinstein JN (1991) An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a “binding site barrier”. Cancer Res 51(18):4776–4784PubMedGoogle Scholar
  49. 49.
    Saga T, Neumann RD, Heya T, Sato J, Kinuya S, Le N, Paik CH, Weinstein JN (1995) Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci USA 92(19):8999–9003PubMedCrossRefGoogle Scholar
  50. 50.
    Graff CP, Wittrup KD (2003) Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res 63(6):1288–1296PubMedGoogle Scholar
  51. 51.
    Thurber GM, Zajic SC, Wittrup KD (2007) Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med 48(6):995–999CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Margaret E. Ackerman
    • 1
  • Cecile Chalouni
    • 2
  • Michael M. Schmidt
    • 3
  • Vivek V. Raman
    • 3
  • Gerd Ritter
    • 4
  • Lloyd J. Old
    • 4
  • Ira Mellman
    • 2
  • K. Dane Wittrup
    • 3
    • 5
  1. 1.Department of BiologyMassachusetts Institute of TechnologyCambridgeUSA
  2. 2.Department of Cell Biology, Ludwig Institute for Cancer ResearchYale University School of MedicineNew HavenUSA
  3. 3.Department of Biological EngineeringMassachusetts Institute of TechnologyCambridgeUSA
  4. 4.Ludwig Institute for Cancer Research, New York BranchMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  5. 5.Department of Chemical EngineeringMassachusetts Institute of TechnologyCambridgeUSA

Personalised recommendations